The overall goal of the research is to create custom-tailored peptide drugs that block the molecular event that initiates and propagates the autoimmune response: the binding of a self-peptide by human leukocyte antigen (HLA) receptors. This strategy could provide a cure for all autoimmune diseases. This grant focuses on RA as a starting point: the specific peptides made in this grant would benefit 240,000 Canadians, 65% of all RA patients.